Use of a clinical trial system implementing blockchain technology
First written in FY2022-Q3. 15 of 20 entries say "Advanced", first in FY2022. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「SUSMED SourceDataSync® is also being used in a physician-led clinical trial conducted by the National Center of Neurology and Psychiatry, targeting myalgic encephalomyelitis/chronic fatigue syndrome; a company-sponsored clinical trial conducted by Heartseed Inc. targeting severe heart failure caused by ischemic heart disease and dilated cardiomyopathy; and a confirmatory study of a therapeutic app in the otolaryngology field being jointly researched and developed with KYORIN Pharmaceutical Co.,Ltd.」
The users of the blockchain-based clinical trial system expanded to multiple physician-led and company-sponsored clinical trials, as well as a confirmatory study of a tinnitus treatment app. - 2026-09-18Advancednews.yahoo.co.jp
「SUSMED, Inc., a Japanese company that develops therapeutic apps and clinical trial support systems, announced on 16 September that a drug tested in a clinical trial using a system based on the company’s blockchain technology had obtained manufacturing and marketing approval in Japan.」
A specific achievement was reported involving drug approval based on the results of a company-sponsored clinical trial using blockchain technology. - FY2026-H1AdvancedAnnual report
「It has been reported that favorable analysis results were obtained, including achievement of the primary endpoint, in Japan Phase III clinical trials conducted by Aculys Pharma, Inc. of the histamine H3 receptor antagonist/inverse agonist Pitolisant in patients with narcolepsy and in patients with excessive daytime sleepiness remaining in association with obstructive sleep apnea syndrome.」
Favorable analysis results, including achievement of the primary endpoints, were reported for 2 blockchain-enabled company-sponsored clinical trials conducted by Aculys Pharma. - FY2025AdvancedAnnual report
「The company's clinical trial system is also being used in the investigator-initiated clinical trial for myalgic encephalomyelitis/chronic fatigue syndrome conducted by National Center of Neurology and Psychiatry, and in the specified clinical study of a therapeutic app targeting premenstrual syndrome and premenstrual dysphoric disorder launched as part of the joint development with あすか製薬株式会社.」
The scope of use of the clinical trial system incorporating blockchain technology has expanded to include a physician-initiated clinical trial conducted by the National Center of Neurology and Psychiatry and specified clinical research conducted with Asuka Pharmaceutical. - FY2025-H1AdvancedAnnual report
「In addition, SUSMED SourceDataSync® is being used in a physician-initiated clinical trial for myalgic encephalomyelitis/chronic fatigue syndrome conducted by the National Center of Neurology and Psychiatry, a National Research and Development Agency.」
In addition to Aculys Pharma's company-sponsored clinical trials and Kyorin Pharmaceutical's specified clinical research, the use of blockchain-enabled SUSMED SourceDataSync® has expanded to a physician-initiated clinical trial conducted by the National Center of Neurology and Psychiatry. - FY2024AdvancedAnnual report
「In October 2023, results were reported from the AMED Research and Development Promotion Network Project, adopted in 2021 and conducted with National University Corporation Tokyo Medical and Dental University, showing that the company's blockchain-enabled method reduced the workload required for monitoring compared with conventional methods. The company will continue working to promote this system, primarily among academia and pharmaceutical companies, with the aim of improving the efficiency of clinical trials.」
Results were reported showing that the blockchain-enabled method reduced monitoring workload compared with conventional methods, adding concrete results toward the system's wider adoption. - FY2024-Q3RestatedAnnual report
「The company will continue to pursue the simultaneous optimization of new drug development costs and improvement in the reliability of clinical trial data through the conduct of blockchain-enabled clinical trials.」
The company continues to pursue a policy of optimizing development costs and improving the reliability of clinical trial data through blockchain-enabled clinical trials. - FY2024-Q2RestatedAnnual report
「The company will continue to pursue the simultaneous optimization of new drug development costs and improvement in the reliability of clinical trial data through the conduct of blockchain-enabled clinical trials.」
The company continues to pursue a policy of optimizing development costs and improving the reliability of clinical trial data through blockchain-enabled clinical trials. - FY2024-Q1AdvancedAnnual report
「The specified clinical study of the tinnitus treatment app launched in the DTx product business is also using SUSMED SourceDataSync®.」
In addition to the 2 existing company-sponsored clinical trials, the clinical trial system using blockchain technology was also used in a specified clinical research study of an app for tinnitus treatment. - FY2023RestatedAnnual report
「The company entered into an outsourcing agreement for the conduct of what was described as the world's first blockchain-enabled company-sponsored clinical trial. As of the date of this document, 2 company-sponsored clinical trials are being conducted by the company.」
The disclosure states that, following the first blockchain-enabled company-sponsored clinical trial, described as the world's first, 2 trials are currently being conducted. - FY2023-Q3AdvancedAnnual report
「A clinical trial using blockchain technology, the first corporate-sponsored clinical trial of its kind in the world according to the company, has begun, and a second corporate-sponsored clinical trial was subsequently also launched by the same company.」
Following the first blockchain-enabled company-sponsored clinical trial, described as the world's first, a second trial has also been launched. - FY2023-Q2AdvancedAnnual report
「A clinical trial using blockchain technology, the first corporate-sponsored clinical trial of its kind in the world according to the company, has begun.」
The corporate-sponsored clinical trial using blockchain technology progressed from the contracting and implementation-preparation stage to the actual trial commencement stage. - FY2023-Q1RestatedAnnual report
「Through clinical trials using blockchain technology, we aim to optimize new drug development costs while improving the reliability of clinical trial data.」
The company continues its policy of using blockchain-based clinical trials to optimize development costs and improve data reliability. - FY2022AdvancedAnnual report
「In June 2022, we entered into a contract with アキュリスファーマ株式会社 for outsourced services related to conducting a clinical trial using blockchain technology, the first such corporate-sponsored clinical trial in the world,」
Specific progress was disclosed regarding the clinical trial system incorporating blockchain technology, namely the execution of an outsourced services agreement for a corporate-sponsored clinical trial. - FY2022-Q3First statedAnnual report
「We entered into respective joint research agreements with National University Corporation Tohoku University concerning the use of blockchain technology in a clinical trial system.」
The first disclosure was made of an initiative to use blockchain technology in a clinical trial system through a joint research agreement with Tohoku University.